Economic Evaluations of Mass Drug Administration: The Importance of Economies of Scale and Scope

Clinical Infectious Diseases

Volumn 66, Issue 8, 2018, Pages 1298-1303

  Turner, Hugo C ^a,b   Toor, Jaspreet ^c   Deirdre Hollingsworth T ^b,d,e   Anderson, Roy M ^c  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

costs; economic evaluations; mass drug administration; Neglected tropical diseases

Indexed keywords

COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MASS DRUG ADMINISTRATION; NEGLECTED TROPICAL DISEASE; PRIORITY JOURNAL; REVIEW; TROPICAL DISEASE; WORLD HEALTH ORGANIZATION; COST BENEFIT ANALYSIS; DRUG COST; META ANALYSIS;

COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; MASS DRUG ADMINISTRATION; WORLD HEALTH ORGANIZATION;

EID: 85045137467     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix1001     Document Type: Review

References (49)

1. World Health Organization. Neglected tropical diseases. Available at: http://www.who.int/neglected-diseases/diseases/en/. Accessed 14 August 2017.
2. Norris J, Adelman C, Spantchak Y, Marano K. Social and Economic Impact Review on Neglected Tropical Disease: Hudson Institute's Center for Science in Public Policy in conjunction with The Global Network for Neglected Tropical Diseases. 2012. Available at: https://www.hudson.org/content/researchattachments/attachment/1083/social-and-economic-impact-review-on-neglected-tropical-diseases-hudson-institute-and-sabin-institute-november-2012.pdf. Accessed 14 August 2017.
3. World Health Organization. Integrating neglected tropical diseases in global health and development. Fourth WHO report on neglected tropical diseases. 2017. Available at: http://www.who.int/neglected-diseases/resources/9789241565448/en/. Accessed 14 August 2017.
4. World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases-A roadmap for implementation. Available at: http://www.who.int/neglected-diseases/NTD-RoadMap-2012-Fullversion.pdf. Accessed 14 August 2017.
5. World Health Organization. Essential medicines donated to control, eliminate and eradicate neglected tropical diseases. Available at: http://www.who.int/neglected-diseases/Medicine-donation-Revised-4-April-2017.pdf?ua=1. Accessed 14 August 2017.
6. Molyneux DH, Savioli L, Engels D. Neglected tropical diseases: progress towards addressing the chronic pandemic. Lancet 2017; 389:312-25.
7. Elbasha EH, Messonnier ML. Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale. Health Econ 2004; 13:21-35.
8. Turner HC, Walker M, French MD, Blake IM, Churcher TS, Basáñez MG. Neglected tools for neglected diseases: mathematical models in economic evaluations. Trends Parasitol 2014; 30:562-70.
9. Johns B, Torres TT; WHO-CHOICE. Costs of scaling up health interventions: a systematic review. Health Policy Plan 2005; 20:1-13.
10. Karlsson G, Johannesson M. Cost-effectiveness analysis and capital costs. Soc Sci Med 1998; 46:1183-91.
11. Turner HC, Truscott JE, Hollingsworth TD, Bettis AA, Brooker SJ, Anderson RM. Cost and cost-effectiveness of soil-transmitted helminth treatment programmes: systematic review and research needs. Parasit Vectors 2015; 8.
12. Kumaranayake L. The economics of scaling up: cost estimation for HIV/AIDS interventions. AIDS 2008; 22(Suppl 1):S23-33.
13. Turner HC, Truscott JE, Fleming FM, Hollingsworth TD, Brooker SJ, Anderson RM. Cost-effectiveness of scaling up mass drug administration for the control of soil-transmitted helminths: a comparison of cost function and constant costs analyses. Lancet Infect Dis 2016; 16:838-46.
14. Brooker S, Kabatereine NB, Fleming F, Devlin N. Cost and cost-effectiveness of nationwide school-based helminth control in Uganda: intra-country variation and effects of scaling-up. Health Policy Plan 2008; 23:24-35.
15. Evans D, McFarland D, Adamani W, et al. Cost-effectiveness of triple drug administration (TDA) with praziquantel, ivermectin and albendazole for the prevention of neglected tropical diseases in Nigeria. Ann Trop Med Parasitol 2011; 105:537-47.
16. Goldman AS, Guisinger VH, Aikins M, et al. National mass drug administration costs for lymphatic filariasis elimination. PLoS Negl Trop Dis 2007; 1:e67.
17. Conteh L, Engels T, Molyneux DH. Socioeconomic aspects of neglected tropical diseases. Lancet 2010; 375:239-47.
18. Turner HC, Bettis AA, Dunn JC, et al. Economic considerations for moving beyond the Kato-Katz technique for diagnosing intestinal parasites as we move towards elimination. Trends Parasitol 2017; 33:435-43.
19. Institute of Medicine (US) Committee on the Economics of Antimalarial Drugs. Saving lives, buying time: economics of malaria drugs in an age of resistance. Washington, DC: National Academies Press, 2004.
20. Guinness L, Wiseman V. Introduction To Health Economics. New York: Open University Press, 2011.
21. Johns B, Baltussen R. Accounting for the cost of scaling-up health interventions. Health Econ 2004; 13:1117-24.
22. Guinness L, Kumaranayake L, Rajaraman B, et al. Does scale matter? The costs of HIV-prevention interventions for commercial sex workers in India. Bull World Health Organ 2005; 83:747-55.
23. Guinness L, Kumaranayake L, Hanson K. A cost function for HIV prevention services: is there a 'u' - shape? Cost Eff Resour Alloc 2007; 5:13.
24. Bishai D, McQuestion M, Chaudhry R, Wigton A. The costs of scaling up vaccination in the world's poorest countries. Health Aff (Millwood) 2006; 25:348-56.
25. Lammie PJ, Fenwick A, Utzinger J. A blueprint for success: integration of neglected tropical disease control programmes. Trends Parasitol 2006; 22:313-21.
26. Ananthakrishnan S, Das PK. Integrated programme for control of geohelminths: a perspective. Natl Med J India 2001; 14:148-53.
27. Brady MA, Hooper PJ, Ottesen EA. Projected benefits from integrating NTD programs in sub-Saharan Africa. Trends Parasitol 2006; 22:285-91.
28. Casey GJ, Sartori D, Horton SE, et al. Weekly iron-folic acid supplementation with regular deworming is cost-effective in preventing anaemia in women of reproductive age in Vietnam. PLoS One 2011; 6:e23723.
29. Boselli G, Yajima A, Aratchige PE, et al. Integration of deworming into an existing immunisation and vitamin A supplementation campaign is a highly effective approach to maximise health benefits with minimal cost in Lao PDR. Int Health 2011; 3:240-5.
30. Fiedler JL, Chuko T. The cost of Child Health Days: a case study of Ethiopia's Enhanced Outreach Strategy (EOS). Health Policy Plan 2008; 23:222-33.
31. Keating J, Yukich JO, Mollenkopf S, Tediosi F. Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: a systematic review. Acta Trop 2014; 135:86-95.
32. Chu BK, Deming M, Biritwum NK, et al. Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation. PLoS Negl Trop Dis 2013; 7:e2584.
33. World Health Organization. Lymphatic filariasis: monitoring and epidemiological assessment of mass drug administration: A manual for national elimination programmes. Available at: http://www.who.int/lymphatic-filariasis/resources/9789241501484/en/. Accessed 14 August 2017.
34. Bishai D, Johns B, Lefevre A, Nair D, Simons E, Dabbagh A. Measles eradication versus measles control: an economic analysis. Vaccines Vaccin 2012; S:3.
35. Turner HC, Walker M, Churcher TS, et al. Reaching the London declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa. Clin Infect Dis 2014; 59:923-32.
36. Turner HC, Truscott JE, Bettis AA, et al. An economic evaluation of expanding hookworm control strategies to target the whole community. Parasit Vectors 2015; 8:570.
37. Turner HC, Walker M, Attah SK, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. Parasit Vectors 2015; 8:167.
38. Stolk WA, ten Bosch QA, de Vlas SJ, Fischer PU, Weil GJ, Goldman AS. Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis. PLoS Negl Trop Dis 2013; 7:e1984.
39. Guyatt HL, Chan MS. An investigation into the interaction between drug efficacy and drug price of praziquantel in determining the cost-effectiveness of school-targeted treatment for Schistosoma mansoni using a population dynamic model. Trop Med Int Health 1998; 3:425-35.
40. Guyatt HL, Chan MS, Medley GF, Bundy DA. Control of Ascaris infection by chemotherapy: which is the most cost-effective option? Trans R Soc Trop Med Hyg 1995; 89:16-20.
41. Guyatt HL, Bundy DA, Evans D. A population dynamic approach to the cost-effectiveness analysis of mass anthelmintic treatment: effects of treatment frequency on Ascaris infection. Trans R Soc Trop Med Hyg 1993; 87:570-5.
42. Carabin H, Guyatt H, Engels D. A comparative analysis of the cost-effectiveness of treatment based on parasitological and symptomatic screening for Schistosoma mansoni in Burundi. Trop Med Int Health 2000; 5:192-202.
43. Guyatt H. Different approaches to modelling the cost-effectiveness of schistosomiasis control. Mem Inst Oswaldo Cruz 1998; 93(Suppl 1):75-84.
44. Guyatt H, Evans D, Lengeler C, Tanner M. Controlling schistosomiasis: the cost-effectiveness of alternative delivery strategies. Health Policy Plan 1994; 9:385-95.
45. Kim YE, Sicuri E, Tediosi F. Financial and economic costs of the elimination and eradication of onchocerciasis (river blindness) in Africa. PLoS Negl Trop Dis 2015; 9:e0004056.
46. Fitzpatrick C, Fleming FM, Madin-Warburton M, et al. Benchmarking the cost per person of mass treatment for selected neglected tropical diseases: an approach based on literature review and meta-regression with web-based software application. PLoS Negl Trop Dis 2016; 10:e0005037.
47. Benchmarks for the cost per person of mass treatment against neglected tropical diseases. Available at: https://healthy.shinyapps.io/benchmark. Accessed 14 August 2017.
48. Turner HC, Bettis AA, Chu BK, et al. Investment success in public health: an analysis of the cost-effectiveness and cost-benefit of the global programme to eliminate lymphatic filariasis. Clin Infect Dis 2017; 64:728-35.
49. Kastner RJ, Sicuri E, Stone CM, Matwale G, Onapa A, Tediosi F. How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis. PLoS Negl Trop Dis 2017; 11:e0005934.